LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
暂无分享,去创建一个
[1] M. Esteller,et al. 5′-CpG island methylation of theLKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer , 2000, Gut.
[2] M. Ciriolo,et al. Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy. , 2014, Biochimica et biophysica acta.
[3] I. Tannock,et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.
[4] Kwok-Kin Wong,et al. A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway , 2013, Nature Cell Biology.
[5] Young Ho Suh,et al. AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. , 2007, Cellular signalling.
[6] L. Chin,et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. , 2009, Molecular cell.
[7] Jun O. Liu,et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.
[8] D. Alessi,et al. Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity , 2013, The Biochemical journal.
[9] I. Grummt,et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. , 2003, Molecular cell.
[10] B. Viollet,et al. Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.
[11] J. Herman,et al. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome , 2000, Oncogene.
[12] A. Marcus,et al. Dysregulation of mTOR activity through LKB1 inactivation , 2013, Chinese journal of cancer.
[13] P. Guldberg,et al. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma , 1999, Oncogene.
[14] M. Rigoulet,et al. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.
[15] Jérôme Boudeau,et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade , 2003, Journal of biology.
[16] L. Neckers,et al. The double edge of the HSP90-CDC37 chaperone machinery: opposing determinants of kinase stability and activity. , 2012, Future oncology.
[17] R. Poulsom,et al. In situ analysis of LKB1/STK11 mRNA expression in human normal tissues and tumours , 2000, The Journal of pathology.
[18] S. Mader,et al. LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer , 2014, International journal of cancer.
[19] Leah E. Mechanic,et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer , 2011, Oncogene.
[20] M. T. McCabe,et al. Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. , 2010, Cancer genetics and cytogenetics.
[21] Shohei Koyama,et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. , 2014, Cancer cell.
[22] Travis J Cohoon,et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. , 2013, Cancer discovery.
[23] E. Montgomery,et al. Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.
[24] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[25] R. Pearson,et al. Dysregulation of RNA polymerase I transcription during disease. , 2013, Biochimica et biophysica acta.
[26] S. Hawley,et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.
[27] David Sidransky,et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.
[28] R. Bristow,et al. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. , 2010, International journal of radiation oncology, biology, physics.
[29] E. Sausville,et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.
[30] A. Marcus,et al. Localization‐specific LKB1 loss in head and neck squamous cell carcinoma metastasis , 2011, Head & neck.
[31] H. You,et al. A role of DNA-dependent protein kinase for the activation of AMP-activated protein kinase in response to glucose deprivation. , 2012, Biochimica et biophysica acta.
[32] G. Merlino,et al. Uncoupling of the LKB1-AMPKα Energy Sensor Pathway by Growth Factors and Oncogenic BRAFV600E , 2009, PloS one.
[33] Jingde Zhu,et al. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis , 2003, Cell Research.
[34] Timothy L. Scott,et al. Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair. , 2014, Antioxidants & redox signaling.
[35] Jingde Zhu,et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma , 2004, BMC Cancer.
[36] G. Mills,et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS , 2010, Proceedings of the National Academy of Sciences.
[37] J. Dice. Lysosomal Pathways of Protein Degradation , 2000 .
[38] Lewis C Cantley,et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[39] Carleen Cullinane,et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.
[40] C. Walker,et al. Differential localization of ATM is correlated with activation of distinct downstream signaling pathways , 2010, Cell cycle.
[41] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[42] G. Mills,et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. , 2014, Cancer research.
[43] T. Tsakiridis,et al. AMP-activated protein kinase (AMPK) beyond metabolism , 2014, Cancer biology & therapy.
[44] H. Ji,et al. Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[45] M. Rossel,et al. Stability of the Peutz–Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37 , 2003, Oncogene.
[46] J. Shupe,et al. LKB1 Represses Focal Adhesion Kinase (FAK) Signaling via a FAK-LKB1 Complex to Regulate FAK Site Maturation and Directional Persistence* , 2013, The Journal of Biological Chemistry.
[47] Jing Wu,et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling , 2010, Proceedings of the National Academy of Sciences.
[48] M. Lawlor,et al. Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. , 2003, The Biochemical journal.
[49] Shi-Yong Sun,et al. LKB1 mutation in large cell carcinoma of the lung. , 2006, Lung cancer.
[50] D. Hardie,et al. Pharmacological activators of AMP‐activated protein kinase have different effects on Na+ transport processes across human lung epithelial cells , 2007, British journal of pharmacology.
[51] Kei Sakamoto,et al. LKB1-dependent signaling pathways. , 2006, Annual review of biochemistry.
[52] S. Singh,et al. Gall-bladder polyps in Peutz-Jeghers syndrome. , 1980, Postgraduate medical journal.
[53] Shi-Yong Sun,et al. Enhancing mTOR-targeted cancer therapy , 2009, Expert opinion on therapeutic targets.
[54] Wei Zhou,et al. LKB1 regulated pathways in lung cancer invasion and metastasis. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] M. Owen,et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.
[56] J. Höhfeld,et al. Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1 , 2012, Oncogene.
[57] Michael Peyton,et al. Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.
[58] Jérôme Boudeau,et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1 , 2004, The EMBO journal.
[59] I. Grummt,et al. AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply , 2009, Proceedings of the National Academy of Sciences.
[60] B. Kemp,et al. β-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK) , 2010, Proceedings of the National Academy of Sciences.
[61] M. Stratton,et al. A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.
[62] Shile Huang,et al. Targeting mTOR signaling for cancer therapy. , 2003, Current opinion in pharmacology.
[63] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[64] R. De Rocco,et al. [Peutz-Jeghers syndrome]. , 1976, Minerva gastroenterologica.
[65] C. Wells,et al. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap , 2013, Oncogene.
[66] Zhaoyuan Fang,et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma , 2014, Nature Communications.
[67] Xiaojin Shi,et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours , 2013, Cancer Chemotherapy and Pharmacology.
[68] K. Kinzler,et al. Genetic instability in colorectal cancers , 1997, Nature.
[69] I. Macara,et al. STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7. , 2008, Molecular biology of the cell.
[70] H C Clevers,et al. Activation of the tumour suppressor kinase LKB1 by the STE20‐like pseudokinase STRAD , 2003, The EMBO journal.
[71] D. Hardie,et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.
[72] H. Ji,et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.
[73] Nora C. Toussaint,et al. In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival , 2014, Pigment Cell & Melanoma Research.
[74] D. Carling,et al. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. , 2007, The Biochemical journal.
[75] D. Moller,et al. New drug targets for type 2 diabetes and the metabolic syndrome , 2001, Nature.
[76] F. McCormick,et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. , 2004, Cancer cell.
[77] Dong Sun Kim,et al. Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers. , 2013, Lung cancer.
[78] L. Cantley,et al. DNA Damage-induced Association of ATM with Its Target Proteins Requires a Protein Interaction Domain in the N Terminus of ATM* , 2005, Journal of Biological Chemistry.
[79] Y. Lee,et al. Involvement of AMPK Signaling Cascade in Capsaicin‐Induced Apoptosis of HT‐29 Colon Cancer Cells , 2007, Annals of the New York Academy of Sciences.
[80] M. Wilkerson,et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.
[81] P. Marignani,et al. Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways , 2013, PloS one.
[82] J. De-Castro Arce,et al. Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1. , 2007, The Biochemical journal.
[83] I. Grummt,et al. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. , 2004, Genes & development.
[84] E. Wang,et al. Overexpression of yes‐associated protein contributes to progression and poor prognosis of non‐small‐cell lung cancer , 2010, Cancer science.
[85] G. Halder,et al. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.
[86] C. Smythe,et al. Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. , 2002, The Biochemical journal.